Evaluation of antifibrotic effect of pirfenidone on human nasal mucosal fibroblast cell culture


Background: One of the main reasons of failure in surgical treatment of primary acquired nasolacrimal duct obstruction is excessive postoperative scarring of the dacryostomy. Despite the variety of procedures designed to prevent this, conflicting evidence of their efficacy and safety provide incentive for further research of antifibrotic therapeutics for adjunctive use in dacryocystorhinostomy.

Aims: To evaluate the antifibrotic effect of pirfenidone on human nasal mucosal fibroblast cell culture.

Materials and methods: Human nasal mucosal fibroblast cell cultures were established using samples obtained from 3 consecutive patients undergoing endonasal endoscopic dacryocystorhinostomy. Cell viability following treatment with pirfenidone was evaluated using MTS-assay. Induced inhibition of cell proliferation and migration was determined using scratch wound assay.

Results: In this study pirfenidone exhibited a significant dose-dependent inhibiting effect on fibroblast proliferation with insignificant cell toxicity. Cell viability following 48 hours of incubation with various pirfenidone concentrations did not drop below 80%. The recovery of the fibroblast monolayer assessed after 24 hours of incubation was 84.88 and 8.26% in the control group, at a drug concentration of 0.15 mg/ml. Cell proliferation and migration was severely inhibited in cell culture specimens treated with pirfenidone compared to controls. The difference between groups was statistically significant (p=0,001).

Conclusions: In our study pirfenidone demonstrated a pronounced antifibrotic effect. It is unlikely that inhibition of proliferation and migration of human nasal mucosal fibroblasts is mediated by cell toxicity of this medication as it was evaluated as low. Nonetheless an in vitro analysis is insufficient to judge pirfenidone’s efficacy and safety in preventing cicatrix formation following dacrycystorhinostomy. 

About the authors

E. L. At'kova

Research Institute of Eye Disease

Email: evg.atkova@mail.ru
ORCID iD: 0000-0001-9875-6217
Moscow Russian Federation

N. N. Krahoveckij

Research Institute of Eye Disease

Email: krahovetskiynn@mail.ru
ORCID iD: 0000-0002-3247-8418
Moscow Russian Federation

V. D. Yartsev

Research Institute of Eye Disease

Email: yartsew@ya.ru
ORCID iD: 0000-0003-2990-8111
Moscow Russian Federation

A. M. Subbot

Research Institute of Eye Disease

Email: kletkagb@gmail.com
ORCID iD: 0000-0002-8258-6011
Moscow Russian Federation

A. N. Gabashvili

Research Institute of Eye Disease

Email: gabashvili.anna@gmail.com
ORCID iD: 0000-0002-4251-3002
Moscow Russian Federation

D. A. Rein

Research Institute of Eye Disease

Author for correspondence.
Email: illefarn@mail.ru
ORCID iD: 0000-0002-0868-3876
Moscow Russian Federation

T. V. Nesterova

Research Institute of Eye Disease

Email: tanesta12@gmail.com
ORCID iD: 0000-0002-1799-1897
Moscow Russian Federation


  1. Liang J, Hur K, Merbs SL, Lane AP. Surgical and anatomic considerations in endoscopic revision of failed external dacryocystorhinostomy. Otolaryngol Head Neck Surg. 2014;150(5):901–905. doi: 10.1177/0194599814524700.
  2. Balikoglu-Yilmaz M, Yilmaz T, Taskin U, et al. Prospective comparison of 3 dacryocystorhinostomy surgeries: external versus endoscopic versus transcanalicular multidiode laser. Ophthal Plast Reconstr Surg. 2015;31(1):13–18. doi: 10.1097/Iop.0000000000000159.
  3. Dave TV, Mohammed FA, Ali MJ, Naik MN. Etiologic analysis of 100 anatomically failed dacryocystorhinostomies. Clin Ophthalmol. 2016;10:1419–1422. doi: 10.2147/Opth.S113733.
  4. Marcet MM, Kuk AK, Phelps PO. Evidence-based review of surgical practices in endoscopic endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction and other new indications. Curr Opin Ophthalmol. 2014;25(5):443–448. doi: 10.1097/Icu.0000000000000084.
  5. Dirim B, Sendul SY, Demir M, et al. Comparison of modifications in flap anastomosis patterns and skin incision types for external dacryocystorhinostomy: anterior-only flap anastomosis with w skin incision versus anterior and posterior flap anastomosis with linear skin incision. ScientificWorldJournal. 2015;2015:170841. doi: 10.1155/2015/170841.
  6. Kansu L, Aydin E, Avci S, et al. Comparison of surgical outcomes of endonasal dacryocystorhinostomy with or without mucosal flaps. Auris Nasus Larynx. 2009;36(5):555–559. doi: 10.1016/j.anl.2009.01.005.
  7. Gibbs DC. New probe for the intubation of lacrimal canaliculi with silicone rubber tubing. Br J Ophthalmol. 1967;51(3):198. doi: 10.1136/bjo.51.3.198.
  8. Chong KK, Lai FH, Ho M, et al. Randomized trial on silicone intubation in endoscopic mechanical dacryocystorhinostomy (SEND) for primary nasolacrimal duct obstruction. Ophthalmology. 2013;120(10):2139–2145. doi: 10.1016/j.ophtha.2013.02.036.
  9. Xie C, Zhang L, Liu Y, et al. Comparing the success rate of dacryocystorhinostomy with and without silicone intubation: a trial sequential analysis of randomized control trials. Sci Rep. 2017;7(1):1936. doi: 10.1038/s41598-017-02070-y.
  10. Zilelioglu G, Ugurbas SH, Anadolu Y, et al. Adjunctive use of mitomycin C on endoscopic lacrimal surgery. Br J Ophthalmol. 1998;82(1):63–66.
  11. Xue K, Mellington FE, Norris JH. Meta-analysis of the adjunctive use of mitomycin C in primary and revision, external and endonasal dacryocystorhinostomy. Orbit. 2014;33(4):239–244. doi: 10.3109/01676830.2013.871297.
  12. Meyer KC, Decker CA. Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag. 2017;13:427–437. doi: 10.2147/TCRM.S81141.
  13. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi: 10.1056/NEJMoa1402582.
  14. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291(1):367–373.
  15. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1):L311–L318.
  16. Lin X, Yu M, Wu K, et al. Effects of pirfenidone on proliferation, migration, and collagen contraction of human tenon’s fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2009;50(8):3763–3770. doi: 10.1167/iovs.08-2815.
  17. Stahnke T, Kowtharapu BS, Stachs O, et al. Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. PLoS One. 2017;12(2):e0172592. doi: 10.1371/journal.pone.0172592.
  18. Zhong H, Sun GY, Lin XC, et al. Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. Invest Ophthalmol Vis Sci. 2011;52(6):3136–3142. doi: 10.1167/iovs.10-6240.
  19. Wang J, Yang YF, Xu JG, et al. Pirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro. Mol Vis. 2013;19:2626–2635.
  20. Khanum BN, Guha R, Sur VP, et al. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Eye (Lond). 2017;31(9):1317–1328. doi: 10.1038/eye.2017.21.
  21. Shin JM, Park JH, Park IH, Lee HM. Pirfenidone inhibits transforming growth factor beta 1-induced extracellular matrix production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy. 2015;29(6):408–413. doi: 10.2500/ajra.2015.29.4221.

Copyright (c) 2018 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies